Proposed FDA Rule Could Limit Pharmacy Compounding

In his latest article for Pharmacy Times, Ned Milenkovich, chair of Much’s Health Care group, discussed a new rule from the U.S. Food and Drug Administration (FDA) that could limit pharmacy compounding. He explains the new rule, termed “Demonstrable Difficulties for Compounding Lists,” and dives into its implications.